Basrah

Benign prostatic hyperplasia (BPH) is a common condition affecting men, especially as they age, with up to 90% of men experiencing it by age 80. This research aims to create an ongoing international registry to collect and analyze demographic and clinical data from men with BPH who receive either medical therapy or surgical treatments. The registry helps track treatment patterns and outcomes worldwide to better understand the effectiveness and complications related to various BPH treatments. The registry collects detailed baseline information including patient-reported symptoms, sexual health, quality of life, urinary flow, and laboratory values such as prostate-specific antigen and testosterone. It also records any complications like bleeding, infections, incontinence, strictures, ejaculation issues, and erectile dysfunction. This data is gathered over a three-year period with no set endpoint, allowing for long-term follow-up and analysis of real-world treatment results. Participants provide medical records which are securely stored and accessed only by authorized users. The study monitors symptoms using standardized scores and quality of life measures, along with clinical tests such as post-void residual urine volume. Regular audits ensure data accuracy, and the registry’s technology supports future integration with patient portals and electronic medical records. The study duration is planned for at least three years, with possible extensions to continue follow-up and research.

Researchers are studying how turoctocog alfa is used in everyday clinical practice for male patients with haemophilia A, a congenital bleeding disorder. This observational retrospective study aims to describe treatment patterns and provide baseline information for managing haemophilia A without changing participants' clinical care. The study focuses on patients who have previously received factor VIII (FVIII) replacement therapy and are now switching to turoctocog alfa. Turoctocog alfa, administered intravenously, is the drug being observed in this study. Data is collected from patients who switch from their previous FVIII therapy to turoctocog alfa. The study does not involve new treatments or interventions but relies on existing medical records uploaded to a special electronic database. Participants' baseline history is recorded at the time they switch to turoctocog alfa, and outcomes are tracked according to their regular clinic visits. The main outcome measured is the annual bleeding rate (ABR) over 12 months following the switch. This helps researchers understand how different turoctocog alfa treatment regimens affect bleeding events in these patients.